Orcoda (ASX:ODA) has signed a multi-year A$8m per annum workforce logistics and facilities management contract with Wagner Corporation at Wellcamp.
Small Caps Stocks
Cluey (ASX:CLU) plans to delist from the ASX, citing thin trading, A$500k in annual cost savings and a less dilutive capital path.
Imagion Biosystems (ASX:IBX) raised A$3.75m at a 24% discount to fund the start of its MagSense HER2 Phase 1b/2 trial in the US.
Cyprium Metals (ASX:CYM) has taken first sulphuric acid at Nifty in 20 years as the Phase 1 copper restart moves into commissioning.
Flagship Minerals (ASX:FLG) sells its RK Lithium Project for US$4m cash, funding its pivot to a focused gold and copper explorer.
Li-S Energy (ASX:LIS) ships its first commercial lithium foil order and secures ISO 9001 certification at its Geelong production line.
StepChange Holdings (ASX:STH) guided FY26 revenue above A$55m and EBITDA of A$5m, while appointing Woodside’s former CIO as Chief Operating Officer.
Aurora Labs (ASX:A3D) has begun shipping AU4 micro gas turbines to SPS under a A$250,000 order, opening a flight-test and distribution pathway.
Activeport Group (ASX:ATV) launches an AI Gateway with FirstWave, earning 6% of GPU consumption revenue across Australia’s fastest-growing neocloud market.
Phase 2 ASX Biotech Prescient Therapeutics (ASX:PTX) has spent the better part of a decade building up to the point it is at now. 2026 has become the year in which the investment case is finally coming into focus. PTX‑100 is the world’s first GGTase‑1 inhibitor to enter human trials, and it remains the only…
